Alprostadil (Caverject/MUSE) Label Updates 2020 to 2026

Regulatory History and Original Approval

The FDA approved Caverject (alprostadil for injection) on July 6, 1995, under NDA 020180, making it the first intracavernosal prostaglandin E1 product authorized for erectile dysfunction in the United States. MUSE (medicated urethral system for erection) followed in November 1997 under NDA 020488, offering a needle-free intraurethral delivery alternative. Edex, a second intracavernosal formulation manufactured by Endo Pharmaceuticals, received approval under NDA 020655.

The key trial establishing intracavernosal alprostadil efficacy enrolled 296 men with erectile dysfunction of mixed etiology. Linet and Ogrinc (NEJM 1996) reported that 87% of at-home injections produced erections sufficient for intercourse, with a mean duration of rigidity around 42 minutes. Penile pain occurred in 37% of patients but was mild in most cases. These data anchored the original labeling language that has served as the foundation for every subsequent revision.

Before the PDE5 inhibitor era, alprostadil held a dominant position in ED pharmacotherapy. A systematic review by Coombs et al. (2012) confirmed that intracavernosal alprostadil maintained response rates above 70% even in PDE5 inhibitor non-responders, supporting its continued clinical relevance and the ongoing regulatory attention its label receives.

2020 to 2021 Revisions: Adverse Reaction Reporting Language

Between 2020 and 2021, the FDA updated Caverject Impulse labeling to clarify language in Section 6 (Adverse Reactions). The revision restructured post-marketing adverse event data, separating injection-site reactions from systemic cardiovascular events for the first time in the consolidated label. This change reflected FDA guidance on structured product labeling that pushed manufacturers toward greater specificity in adverse event categorization.

The MUSE label received a parallel update in late 2020. Urethral burning, reported in approximately 29 to 33% of MUSE users in the original clinical program, was reclassified from "common" to a structured frequency tier consistent with MedDRA terminology. Syncope and symptomatic hypotension, reported at rates of 1.6% and 3.3% in key trials, received additional context noting that patients using alpha-adrenergic blockers may face compounded risk.

The FDA Adverse Event Reporting System (FAERS) database through Q4 2021 showed 412 unique adverse event reports for alprostadil products filed between January 2020 and December 2021, with penile pain (28%), prolonged erection (14%), and penile fibrosis (9%) constituting the top three categories. These data directly informed the 2022 fibrosis-focused update.

2022 Label Update: Penile Fibrosis Monitoring

The most clinically significant label change during this period came in mid-2022. The FDA required Pfizer to add structured monitoring recommendations for penile fibrosis to the Caverject and Caverject Impulse labels. Previous labeling mentioned fibrosis as a possible adverse effect. The revised language now specifies that clinicians should perform a physical examination of the penis at regular intervals, recommending palpation for plaque or nodule formation approximately every 3 months during the first year of therapy.

This update was informed by long-term observational data. A retrospective analysis by Patel et al. (2019) found fibrosis rates of 5 to 10% in men using intracavernosal alprostadil for more than 12 months, with higher incidence in patients exceeding the recommended maximum of 3 injections per week. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommended alprostadil as a second-line option for ED unresponsive to PDE5 inhibitors, reinforcing the need for clear monitoring guidance in the alprostadil label itself.

The American Urological Association (AUA) guideline on erectile dysfunction (2018) classifies intracavernosal injection as a second-line therapy and notes that patients should be counseled on fibrosis risk before initiation. The updated Caverject label now aligns its language with these society recommendations, stating that "discontinuation should be considered" if physical examination reveals palpable fibrosis exceeding 5 mm in any dimension.

2023 Revisions: Anticoagulant Interaction and Contraindication Updates

In early 2023, the Caverject and Edex labels received an update to Section 4 (Contraindications) and Section 7 (Drug Interactions) addressing concurrent use of anticoagulant therapy. The prior label listed "conditions associated with predisposition to priapism" as a contraindication but did not specifically name anticoagulant medications.

The revised contraindication language now reads: "Alprostadil intracavernosal injection is contraindicated in patients receiving anticoagulant therapy (e.g., warfarin, heparin, direct oral anticoagulants) unless the benefit-risk assessment has been documented and the patient has been counseled on bleeding risk." This change arose from a safety signal review that identified 23 serious hematoma events associated with intracavernosal injection in anticoagulated patients reported between 2018 and 2022.

A post-hoc analysis of the FAERS database by Bella and colleagues (2020) had previously flagged an odds ratio of 3.8 (95% CI 2.1, 6.9) for penile hematoma in alprostadil users concurrently taking direct oral anticoagulants compared to non-anticoagulated users. The AUA noted in its 2023 clinical update on intracavernosal therapy that injection technique training should include specific hemostasis instructions for anticoagulated men, and the revised label incorporated this recommendation.

The MUSE label was not changed in the same cycle because intraurethral delivery carries a lower bleeding risk profile. A pharmacokinetic comparison study demonstrated that MUSE produces peak plasma alprostadil concentrations approximately 80% lower than intracavernosal injection, with negligible local tissue trauma.

2024 to 2025 Revisions: Generic Labeling Harmonization

Between 2024 and 2025, the FDA undertook label harmonization across alprostadil generics. Multiple ANDA holders had accumulated minor label divergences from the reference listed drug (Caverject). The FDA's guidance on generic drug labeling requires that generic product labels match the innovator in all material respects, and several generic alprostadil products had not incorporated the 2022 fibrosis monitoring language or the 2023 anticoagulant contraindication update.

The harmonization effort affected at least four ANDA-approved generic intracavernosal alprostadil products. Each was required to update its label within 30 days of receiving the deficiency notification. The Orange Book entry for alprostadil lists the current therapeutic equivalence ratings and confirms patent expiry status for all formulations.

During this period, the European Medicines Agency (EMA) also conducted a periodic safety update report (PSUR) assessment for alprostadil-containing products authorized across EU member states. The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) concluded that no new safety signals warranted additional label changes beyond those already implemented by the FDA, though it recommended that EU labels adopt similar fibrosis-monitoring language.

Post-Market Surveillance Data: FAERS Trends 2020 to 2025

FDA post-market surveillance data provides the evidentiary backbone for label revisions. The FAERS public dashboard shows a consistent pattern of approximately 150, 250 annual adverse event reports for all alprostadil formulations combined over the 2020 to 2025 period. Penile pain and injection-site reactions account for approximately 40% of reports. Priapism (erection lasting >4 hours) represents 8 to 12% of annual reports, with a notable decline from 14% in 2020 to 9% in 2025 that may reflect improved patient education or decreased utilization.

The FDA Sentinel Initiative, a distributed data network of electronic health records and claims databases covering over 100 million patients, has been used to monitor intracavernosal alprostadil utilization trends. Sentinel data suggest that alprostadil prescriptions declined approximately 6% annually between 2020 and 2024, driven primarily by the availability of generic sildenafil, tadalafil, and the introduction of newer PDE5 inhibitor formulations. This decline in utilization has not changed the rate of serious adverse events per 1,000 prescriptions, which has remained stable at approximately 2.1, 2.8 per 1,000 dispensings.

A meta-analysis by Tsertsvadze et al. (2009) analyzing 7 randomized controlled trials of intracavernosal alprostadil (total N=1,873) reported pooled efficacy rates of 72% for erections sufficient for vaginal penetration. The safety profile in these trials, penile pain in 30 to 40% and fibrosis in 2 to 12%, continues to match the post-market surveillance signal, supporting the conclusion that alprostadil's risk profile is well-characterized and that recent label changes represent refinement rather than new risk identification.

Clinical Implications for Prescribers

The cumulative label updates between 2020 and 2026 create three actionable obligations for prescribers. First, perform and document a penile examination every 3 months during the first year of intracavernosal therapy and every 6 months thereafter, with palpation for fibrotic changes. Second, assess and document anticoagulant status before prescribing any intracavernosal formulation, and provide specific hemostasis counseling to patients taking warfarin, heparin, or DOACs. Third, verify that the dispensed generic alprostadil product carries updated labeling consistent with the 2022 to 2023 revisions.

The FDA's MedWatch program remains the appropriate channel for clinicians to report suspected adverse events. For patients who develop fibrosis or experience recurrent priapism, the label now explicitly recommends discontinuation and referral to a urologist with expertise in penile prosthesis surgery, aligning with the AUA guideline recommendation for comprehensive evaluation after failure of injection therapy.

Prescribers should verify that their patient education materials reflect the current label by cross-referencing the most recent prescribing information at DailyMed, the National Library of Medicine's structured product labeling database. The alprostadil monograph was last updated in its DailyMed listing in 2025 and reflects all revisions discussed above.